ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Investigational COVID-19 Vaccine Lot A

Also written as “Investigational COVID-19 Vaccine Lot B”.

Its studies are mostly in Influenza, Human, led by Moderna.

Furthest: phase 2, since Mar 5, 20251 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Moderna10 open or runningphase 2since Mar 5, 2025Mar 5, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 5, 2025First study: phase 2 study in Influenza, HumanFirst studyNCT06864143 · 1,320 enrolled · United States

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Investigational COVID-19 Vaccine Lot A”name, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06864143Influenza, Human · United States2CompletedOct 13, 20251,320

How it is read

Names in the registry

  • “Investigational COVID-19 Vaccine Lot A”, 1 entry
  • “Investigational COVID-19 Vaccine Lot B”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.